Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) EPS (Basic) (2016 - 2025)

China Pharma Holdings' EPS (Basic) history spans 16 years, with the latest figure at -$0.17 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 63.04% year-over-year to -$0.17; the TTM value through Dec 2025 reached -$0.74, up 72.79%, while the annual FY2025 figure was -$0.74, 72.69% up from the prior year.
  • EPS (Basic) reached -$0.17 in Q4 2025 per CPHI's latest filing, roughly flat from -$0.17 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.02 in Q1 2021 to a low of -$3.22 in Q4 2022.
  • Average EPS (Basic) over 5 years is -$0.45, with a median of -$0.23 recorded in 2022.
  • Peak YoY movement for EPS (Basic): crashed 2200.0% in 2021, then surged 99.38% in 2023.
  • A 5-year view of EPS (Basic) shows it stood at -$0.69 in 2021, then crashed by 366.67% to -$3.22 in 2022, then soared by 99.38% to -$0.02 in 2023, then crashed by 2200.0% to -$0.46 in 2024, then skyrocketed by 63.04% to -$0.17 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's EPS (Basic) are -$0.17 (Q4 2025), -$0.17 (Q3 2025), and -$0.16 (Q2 2025).